Drug
TAK-041 clinical trials
Also written TAK-041.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses TAK-041 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDDCompletedPhase 2Neurocrine BiosciencesNCT05165394Written as NBI-1065846
- A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)CompletedPhase 1Neurocrine BiosciencesNCT02959892Written as TAK -041
- Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics StudyCompletedPhase 1Neurocrine BiosciencesNCT02748694Written as TAK-041
- A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable SchizophreniaCompletedPhase 2Neurocrine BiosciencesNCT03319953Written as TAK-041